Multitarget Pharmacological Mechanisms and Safety Profiles of Six Ethnobotanically Prioritized Indonesian Medicinal Plants for Cardiometabolic Disorders: A Systematic Review Authors: Febrina A Saputri, Raden M Febriyanti, Zulfan Zazuli, Callista A Mulyadi, Citra Aulia Rahma, Made A N D Putri, Najwa Kirana Published: 2026 ABSTRACT AbstractThis systematic review, conducted per PRISMA guidelines, examined the pharmacological activities and safety of six ethnobotanically prioritized medicinal plants for cardiometabolic disease: Gynura procumbens, Mimosa pudica, Tithonia diversifolia, Leucaena leucocephala, Smallanthus sonchifolius, and Syzygium cumini. Searches of PubMed and Scopus yielded 81 records, of which 66 studies met eligibility criteria, comprising in silico (n = 15), in vitro (n = 43), in vivo/clinical (n = 40), and safety/toxicity (n = 54) evidence. Mechanistic findings were categorized across glucose regulation, insulin signaling, lipid metabolism, vascular/endothelial function, inflammation, oxidative stress, and renal/cardiovascular complications. Gynura procumbens showed the broadest pharmacological activity, spanning glucose-lowering, lipid-modulating, vasorelaxant, and anti-inflammatory effects, alongside the most favorable short-term safety profile. Tithonia diversifolia, Leucaena leucocephala, and Smallanthus sonchifolius demonstrated robust multitarget antidiabetic activity in vitro but with accompanying hepatic, renal, or reproductive toxicity signals that may limit translation. At the same time, evidence for Mimosa pudica and Syzygium cumini remained largely preclinical, in silico, or polyherbal formulation-based. Safety data varied considerably across species and preparations, and long-term data on chronic toxicity, reproductive toxicity, and genotoxicity remain limited overall. These findings should be interpreted in light of the substantial heterogeneity in extraction methods and plant preparations, the general lack of standardized extracts, and the absence of a meta-analysis across the included studies. Overall, this review underscores the therapeutic potential of ethnobotanically selected medicinal plants for cardiometabolic disorders while highlighting the need for standardized, mechanistically validated, and clinically oriented research before therapeutic translation.Keywords: Indonesia medicinal plants, cardiovascular, ethnobotany, metabolic disease, diabetes mellitus, toxicity, safety Introduction Cardiovascular and metabolic diseases represent a closely interconnected group of chronic disorders that include diabetes mellitus, hypertension, dyslipidemia, obesity-related metabolic dysfunction, endothelial dysfunction, and atherosclerotic cardiovascular disease.1,2 A single pathological event does not drive these conditions. These conditions arise from complex interactions among insulin resistance, impaired glucose homeostasis, chronic low-grade inflammation, oxidative stress, altered lipid metabolism, endothelial dysfunction, mitochondrial stress, and vascular remodeling.3–6 In diabetes mellitus, persistent hyperglycemia results from impaired insulin secretion, reduced insulin sensitivity, or both, and is frequently accompanied by disturbances in lipid, carbohydrate, and protein metabolism.7–11 The chronicity and multisystemic nature of cardiometabolic diseases therefore require therapeutic strategies that can simultaneously modulate multiple molecular and physiological pathways.12,13 The global burden of cardiometabolic disease underscores the clinical significance of this review. According to the 2024 International Diabetes Federation (IDF) Diabetes Atlas, an estimated 589 million adults aged 20–79 years (11.1% of the global adult population) were living with diabetes in 2024, a figure projected to reach 853 million by 2050.14 The World Health Organization estimates that 1.4 billion adults aged 30–79 years had hypertension in 2024, with fewer than one in four having their blood pressure adequately controlled. 15 Obesity affected approximately 16% of adults worldwide (roughly 878 million individuals) in 2022, a prevalence that has more than quadrupled since 1990.16 Cardiovascular disease remains the leading cause of death globally, accounting for an estimated 19.8 million deaths in 2022, approximately 32% of all deaths worldwide.17 These converging epidemics of diabetes, hypertension, obesity, and cardiovascular disease illustrate the scale of the clinical need that multitarget, ethnobotanically informed therapeutic strategies aim to address. Current pharmacological management of cardiometabolic diseases relies on agents that target specific components of disease progression, including intestinal carbohydrate digestion, pancreatic insulin secretion, incretin signaling, hepatic glucose production, peripheral insulin sensitivity, vascular tone, lipid metabolism, and inflammatory processes.18–20 However, because cardiometabolic disorders are characterized by network-level dysregulation, single-target interventions may be insufficient to fully address the overlapping metabolic, vascular, inflammatory, and oxidative components of disease.11,21,22 Shared mechanisms such as chronic low-grade inflammation, oxidative stress, endothelial dysfunction, impaired nitric oxide bioavailability, immune-metabolic activation, and vascular remodeling further support the need for therapeutic strategies that can simultaneously modulate multiple biological targets.22,23 Although conventional single-target approaches, including lipid-lowering, antihypertensive, and glucose-lowering therapies, have demonstrated clinical efficacy, disease-specific treatment models may produce fragmented management, polypharmacy, and incomplete correction of the broader cardiometabolic disturbance.11,23–25 Consequently, increasing attention has been directed toward multitarget therapeutic strategies, including agents that regulate glucose, lipid, blood pressure, endothelial, inflammatory, and renal pathways in parallel. The cardiometabolic benefits of PPAR agonists, SGLT2 inhibitors, GLP-1 receptor agonists, fixed-dose lipid-lowering combinations, and antihypertensive combinations illustrate the therapeutic value of targeting multiple interconnected pathways rather than isolated endpoints.26,27 Medicinal plants are important sources of structurally diverse bioactive compounds with potential relevance to multitarget cardiometabolic modulation. Phytochemical classes such as flavonoids, phenolic acids, tannins, terpenoids, alkaloids, saponins, and sesquiterpene lactones have been associated with enzyme inhibition, receptor interaction, antioxidant activity, anti-inflammatory signaling, endothelial protection, insulin-sensitizing effects, and lipid-regulatory activity.28–31 Plant-derived compounds such as curcumin, quercetin, resveratrol, and other polyphenols have been shown to interact with molecular pathways involved in inflammation, oxidative stress, metabolic homeostasis, endothelial protection, and cardiovascular function.29,30,32 Nevertheless, the pharmacological relevance of medicinal plants cannot be inferred solely from traditional use, phytochemical richness, or isolated in vitro activity. Their translational potential depends on the reproducibility of extract preparation, the adequacy of botanical and phytochemical characterization, the consistency of efficacy across experimental models, the biological plausibility of mechanistic claims, dose–response relationships, bioavailability, and the robustness of safety and toxicological evidence.29 Despite this pharmacological promise, most plant-derived compounds that show favorable activity in preclinical models fail to progress to clinically useful therapies. This translational gap arises from several compounding factors: poor aqueous solubility and low oral bioavailability of many phenolic and terpenoid constituents; batch-to-batch variability in extract composition arising from differences in plant provenance, harvest season, and extraction solvent; the absence of standardized reference markers against which efficacy and safety can be benchmarked; limited pharmacokinetic and dose–response data to guide first-in-human dosing; and the scarcity of well-designed, adequately powered randomized clinical trials, most existing evidence for candidate species being confined to in vitro, in vivo animal, or in silico models. As a result, many phytochemicals with compelling multitarget mechanistic profiles never accumulate the standardized, reproducible evidence base required for regulatory or clinical translation. Systematic review of ethnobotanically prioritized medicinal plants offers a structured approach to bridging this gap. Rather than screening candidate species at random, ethnobotanical prioritization uses documented traditional use, cross-cultural consensus, and regional prevalence of use as a filter to identify taxa with a higher prior probability of genuine bioactivity, thereby focusing scarce experimental and clinical resources on the most promising candidates. Synthesizing the resulting, often fragmented, body of in silico, in vitro, in vivo, and toxicological evidence within a single systematic framework allows convergent mechanistic signals to be distinguished from isolated or contradictory findings, clarifies which species have progressed furthest toward translational readiness, and identifies the specific evidentiary gaps, such as standardization, pharmacokinetics, or clinical validation, that must be addressed before ethnobotanically prioritized species can be considered for drug development. Indonesia provides a particularly relevant context for such evaluation because traditional plant-based therapy remains embedded within diverse local medical systems across the archipelago. Previous ethnobotanical and ethnopharmacological syntheses have documented extensive use of medicinal plants for diabetes and related metabolic disorders in Indonesia, including 132 antidiabetic plant species reported from 67 studies across 18 provinces and 37 ethnic groups.33 This broader evidence indicates that Indonesian ethnomedicine represents a substantial reservoir of candidate taxa for cardiometabolic research. In the present review, Gynura procumbens, Mimosa pudica, Tithonia diversifolia, Leucaena leucocephala, Smallanthus sonchifolius, and Syzygium cumini were selected through an ethnobotanically guided prioritization process based on ethnobotanical studies in Indonesia.34–39 The six species were prioritized according to four criteria applied across these ethnobotanical sources: (1) frequency of documented traditional use for diabetes, hypertension, or related metabolic complaints; (2) consensus of use across multiple, geographically distinct Indonesian ethnic groups; (3) broad geographical distribution or cultivation across the archipelago, supporting accessibility and reproducibility of sourcing; and (4) existing availability of at least preliminary pharmacological or phytochemical evidence permitting further mechanistic evaluation. The selection was further triangulated against published Indonesian studies and related ethnopharmacological evidence. For example, Smallanthus sonchifolius has been explicitly reported as a traditional remedy for diabetes in Rejang Lebong District, Bengkulu.39 Gynura procumbens has been documented as an antihypertensive medicinal plant used by the Malay community in Sari Makmur Village, West Kalimantan.38 Syzygium cumini has been included in Indonesian antidiabetic plant syntheses and evaluated as part of indigenous Indonesian ethnomedicinal herbal infusions for diabetes-related outcomes.33,40 Tithonia diversifolia has been reported in Indonesian medicinal plant research and evaluated experimentally for antidiabetic-relevant targets, including dipeptidyl peptidase-4 inhibition.41 Taken together, these taxa provide a focused yet culturally grounded framework for evaluating whether ethnobotanically prioritized Indonesian medicinal plants demonstrate coherent multitarget mechanisms and acceptable safety profiles for future cardiometabolic drug discovery, standardization, and translational development. Accordingly, this systematic review critically evaluated published pharmacological and toxicological evidence for six ethnobotanically prioritized Indonesian medicinal plants, with an emphasis on their mechanistic relevance to glucose homeostasis, lipid metabolism, vascular and endothelial function, inflammation, oxidative stress, and safety. Materials and Methods Study Design and Candidate Plant Selection This systematic review evaluated the pharmacological mechanisms and safety profiles of six ethnobotanically prioritized medicinal plants with potential relevance to cardiometabolic diseases: Gynura procumbens, Mimosa pudica, Tithonia diversifolia, Leucaena leucocephala, Smallanthus sonchifolius, and Syzygium cumini. The review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.42 Eligibility criteria were defined a priori using a PICOS-oriented framework adapted for ethnobotanical, ethnopharmacological, experimental, toxicological, and computational evidence, as summarized in Table 1. Table 1PICOS FrameworkPICOS ElementDefinition for This Systematic ReviewInclusion CriteriaExclusion CriteriaPopulation/ProblemCardiometabolic disease models, conditions, or mechanisms relevant to diabetes, hypertension, dyslipidemia, and obesity-related metabolic dysfunction.Studies evaluating cardiometabolic disease-related outcomes in humans, animals, cells, enzymes, tissues, or validated computational modelsStudies unrelated to cardiometabolic disease, metabolic regulation, vascular function, inflammation, oxidative stress, or safetyIntervention/ExposurePreparations or constituents derived from six ethnobotanically prioritized medicinal plants: Gynura procumbens, Mimosa pudica, Tithonia diversifolia, Leucaena leucocephala, Smallanthus sonchifolius, and Syzygium cuminiCrude extracts, aqueous preparations, hydroalcoholic extracts, solvent extracts, standardized extracts, fractions, enriched fractions, isolated compounds, nanoparticles, endophytic preparations, or computationally evaluated phytoconstituents from the target speciesStudies on non-target species; studies where the plant identity was unclear; polyherbal formulations where the contribution of the target species could not be interpretedComparatorExperimental or computational comparator used to determine pharmacological or toxicological relevanceVehicle control, untreated control, negative control, disease-model control, standard pharmacological drug, reference inhibitor, positive control, co-crystallized ligand, or reference ligandExperimental studies without an interpretable comparator, except ethnobotanical field studies where comparator is not applicableOutcomesCardiometabolic efficacy, mechanistic activity, phytochemical characterization, and safety/toxicity evidenceAntihyperglycemic, antidiabetic, antihypertensive, hypolipidemic, anti-obesity, insulin-sensitizing, vasorelaxant, endothelial-protective, anti-inflammatory, antioxidant, anti-atherosclerotic, nephroprotective, or cardioprotective outcomes; enzyme inhibition; receptor interaction; molecular docking; and ADME-TOutcomes limited to agriculture, cosmetics, food processing, antimicrobial activity alone, or other non-cardiometabolic endpoints without mechanistic or safety relevanceStudy designPublished primary studies providing ethnobotanical, ethnopharmacological, experimental, clinical, toxicological, or computational evidenceEthnobotanical field studies, ethnopharmacological studies, in vitro studies, in vivo studies, clinical studies, toxicological studies, and in silico studiesReviews, systematic reviews, meta-analyses, editorials, letters, commentaries, conference abstracts, book chapters, and non-primary literature. PICOS Framework This review was not prospectively registered in PROSPERO; this is acknowledged as a limitation, and the full protocol, including the a priori PICOS criteria and mechanistic domain framework in Table 1, is reported here in accordance with PRISMA 2020 reporting standards to maximize methodological transparency. Information Sources and Search Strategy Systematic searches were conducted in Scopus and PubMed from database inception to 10th February 2026. These two databases were selected because, together, they provide the broadest indexing of peer-reviewed pharmacological, toxicological, and ethnobotanical literature relevant to this review, with substantial complementary coverage of biomedical, life-science, and pharmacy journals; PubMed indexes MEDLINE and life-science content in depth, while Scopus additionally captures pharmacology-, chemistry-, and agriculture-oriented journals in which ethnobotanical and phytochemical studies are frequently published. Manual screening of reference lists from included and related articles was used to supplement recall beyond these two databases. This two-database restriction is nonetheless acknowledged as a limitation in the Discussion. No language restriction was applied at the search stage; non-English records that passed title/abstract screening were translated for full-text assessment. Grey literature (theses, conference proceedings, and institutional repositories) was not systematically searched, and this is acknowledged as a limitation in the Discussion. Additional studies were identified by manual screening of reference lists from relevant articles and reviews. The search strategy combined three concept blocks: plant identity, cardiometabolic disease terms, and mechanism or safety terms, connected using the Boolean operators AND (between concept blocks) and OR (within each concept block); for example, the PubMed query for one species took the form (“Gynura procumbens” OR “sambung nyawa”) AND (diabetes OR hyperglycemia OR hypertension OR dyslipidemia OR “metabolic syndrome”) AND (mechanism OR toxicity OR safety). The full, database-specific search strings for all six species are also reproduced in the Supplementary Material for transparency, in addition to Supplementary File 1. Plant terms included accepted scientific names, synonyms, historical names, and relevant common names for the six target species. Cardiometabolic terms included diabetes, hyperglycemia, insulin resistance, hypertension, dyslipidemia, obesity, metabolic syndrome, endothelial dysfunction, atherosclerosis, cardiovascular disease, and cardiometabolic complications. Mechanistic and safety terms included α-glucosidase, α-amylase, DPP-4, ACE, PPARγ, AMPK, PI3K/Akt, GLUT4, oxidative stress, inflammation, nitric oxide, molecular docking, ADME, toxicity, cytotoxicity, hepatotoxicity, nephrotoxicity, mutagenicity, and safety. Database-specific syntax was adapted for each source. The complete search strategies are provided in Supplementary File 1. Study Selection All retrieved records were exported to a reference management system, and duplicates were removed. Titles and abstracts were screened against the predefined eligibility criteria, followed by full-text assessment of potentially relevant records. Reasons for exclusion at the full-text stage were documented. Screening was performed independently by two reviewers (FAS and RMF), with disagreements resolved by discussion or consultation with a third reviewer (ZZ). Data Extraction Data were extracted using a structured extraction workbook. Extracted variables included study identification, plant species, plant part, authentication method, preparation type, extraction method, solvent system, standardization marker, phytochemical constituents, study model, assay type, dose or concentration, comparator, pharmacological endpoint, mechanistic endpoint, safety outcome, and main findings. For in silico studies, extracted data included target protein, ligand or phytoconstituent, binding score, comparator ligand, ADME-T prediction, and mechanistic interpretation. For in vitro studies, extracted data included enzyme system or cell line, assay type, concentration range, positive control, readout, and outcome. For in vivo or clinical studies, extracted data included model, intervention dose, duration, comparator, cardiometabolic endpoint, biochemical marker, histopathological finding, and treatment effect. Safety data included LD50, NOAEL, cytotoxicity, mutagenicity, biochemical toxicity markers, organ-specific toxicity, histopathology, mortality, and adverse observations. Mechanistic Domain Mapping To enable comparative synthesis, findings were mapped into predefined cardiometabolic domains: glucose absorption and carbohydrate digestion; insulin signaling and glucose homeostasis; lipid metabolism and adipometabolic regulation; vascular tone and endothelial function; inflammation and immune-metabolic signaling; oxidative stress and cytoprotection; renal or cardiometabolic complication-related mechanisms; and safety or toxicity. This framework was used to compare mechanistic breadth and evidence convergence across species. Quality and Reliability Assessment Methodological reliability was appraised descriptively according to study type. In vivo studies were assessed using key domains adapted from experimental risk-of-bias guidance, including model appropriateness, randomization, control selection, dose reporting, blinding, outcome measurement, and completeness of reporting.43 Toxicological studies were assessed using reliability principles consistent with the Toxicological Data Reliability Assessment Tool, including test substance characterization, dose description, exposure duration, endpoint validity, control adequacy, and reporting transparency.44 In vitro studies were assessed based on assay appropriateness, concentration range, positive control use, replication, viability control, and consistency between claims and readouts. In silico studies were assessed based on target relevance, ligand identification, docking protocol transparency, comparator use, validation procedure, and ADME-T reporting. This appraisal was descriptive rather than based on a single validated, study-type-agnostic risk-of-bias instrument (eg, SYRCLE for animal studies or a formalized ToxRTool scoring scheme), because no validated tool spanning in silico, in vitro, in vivo, and toxicological evidence simultaneously currently exists. The domains applied were adapted from established guidance for each evidence type, as referenced above, and are acknowledged as a methodological limitation in the Discussion. Data Synthesis Because the included studies were heterogeneous in species, plant part, extract type, solvent, dose, model, endpoint, and outcome metric, meta-analysis was not performed; pooling effect sizes across such structurally different comparisons (eg, in silico binding scores, in vitro half-maximal inhibitory concentrations, and in vivo fasting-glucose changes) would not yield a statistically or biologically meaningful summary estimate, and the very small number of studies sharing an identical species, preparation, model, and outcome metric would in most cases preclude a statistically robust pooled estimate even within a single comparison. Findings were therefore synthesized narratively and comparatively by species, preparation type, study model, mechanistic domain, efficacy endpoint, and safety profile. Greater interpretive weight was assigned to studies with botanical authentication, phytochemical characterization, appropriate comparators, dose–response evaluation, and concordant in vitro and in vivo evidence. In silico findings were interpreted as hypothesis-generating unless supported by experimental data. Safety evidence was synthesized separately to identify species with favorable, uncertain, or potentially limiting benefit–risk profiles. Results Study Selection The predefined search strategy identified 81 records from PubMed and Scopus, comprising 38 records from PubMed and 43 records from Scopus. After removal of 11 duplicate records, 70 unique records remained for screening and eligibility assessment. Four articles were excluded at the full-text eligibility stage, each for a distinct, prespecified reason: one was a narrative (non-systematic) review that did not report extractable primary data; one was a secondary systematic review summarizing findings already captured through the primary studies it cited; one reported only agricultural or nutritional outcomes (crop yield and proximate composition) without a cardiometabolic, mechanistic, or safety endpoint; and one could not be verified as evaluating the correct target species because the plant material was not authenticated and voucher information was unavailable. Therefore, 66 studies met the eligibility criteria and were included in the qualitative synthesis and data extraction (Figure 1). The complete list of included studies and extracted study-level characteristics is provided in Supplementary File 2. PRISMA Flow Diagram. Source: Page MJ et al. BMJ 2021;372:n71. doi: 10.1136/bmj.n71. General Characteristics of Included Studies The 66 included studies covered six ethnobotanically prioritized medicinal plants: Gynura procumbens (n = 14), Tithonia diversifolia (n = 12), Smallanthus sonchifolius (n = 12), Leucaena leucocephala (n = 11), Mimosa pudica (n = 10), and Syzygium cumini (n = 7) (Table 2). The evidence base was methodologically heterogeneous and included in silico studies (n = 15), in vitro studies (n = 43), in vivo or clinical studies (n = 40), and safety or toxicity evaluations (n = 54). These categories were not mutually exclusive because several studies combined computational, in vitro, in vivo, phytochemical, and toxicological assessments. The distribution of included studies by species and evidence type is presented in Table 2 and Figure 2. The complete list of the evidence type is provided in Supplementary File 3. Table 2Distribution of Included Studies by Target SpeciesTarget SpeciesNumber of Included StudiesMain Evidence FocusKey Interpretation for SynthesisGynura procumbens14Antihyperglycemic, antihypertensive/vasorelaxant, anti-inflammatory, endothelial-protective, wound-healing, and safety evidenceBroadest evidence coverage among the six taxa, with mechanistic relevance to glucose homeostasis, vascular function, inflammation, and endothelial protectionMimosa pudica10Enzyme inhibition, glucose uptake, antioxidant activity, insulin-associated pathways, and preliminary toxicity predictionEvidence is concentrated in in vitro and in silico models, with limited in vivo validation for cardiometabolic endpointsTithonia diversifolia12Antidiabetic, DPP-4/multitarget computational evidence, anti-inflammatory, nephroprotective, anti-atherosclerotic, and toxicity evidenceMechanistically broad, but safety interpretation requires caution because hepatotoxicity, nephrotoxicity, and mutagenicity signals were reported in some studiesLeucaena leucocephala11α-glucosidase/α-amylase inhibition, insulin-related effects, endophytic bioactivity, antioxidant activity, and mimosine-related toxicityPharmacological potential must be interpreted alongside toxicological concerns, particularly those associated with mimosine exposureSmallanthus sonchifolius12Antidiabetic effects, insulin modulation, DPP-4/SGLT-2-related computational evidence, oxidative stress, diabetic complications, and toxicityEvidence supports metabolic relevance, but renal and genotoxicity signals require careful benefit–risk interpretationSyzygium cumini7Antidiabetic, hypolipidemic, antioxidant, atheroprotective, formulation-level, and safety evidenceEvidence supports glucose- and lipid-modulating potential, although several studies involve formulation-level or combination preparations Distribution of Included Studies by Target Species Evidence type distribution by target species. Plant Materials, Extraction Methods, and Phytochemical Characterization The included studies showed marked heterogeneity in plant material, extraction procedure, solvent system, and phytochemical characterization (Table 3). Leaves were the dominant plant material, particularly for Gynura procumbens, Tithonia diversifolia, Smallanthus sonchifolius, and Syzygium cumini. Extraction procedures included maceration, ultrasonication, infusion, decoction, percolation, Soxhlet extraction, solvent partitioning, ion-exchange extraction, endophyte fermentation, formulation-based preparations, and in silico phytoconstituent screening. Solvent systems were dominated by ethanol, hydroethanolic mixtures, water, methanol, and organic solvent fractions. Phytochemical characterization ranged from qualitative phytochemical screening to chromatographic, spectrometric, and computational profiling. This variability limited direct quantitative comparison and supported narrative synthesis. Table 3Plant Materials, Extraction Methods, Solvent Systems, and Phytochemical Identification Reported in the Included StudiesSpeciesExtraction/Preparation MethodsPlant MaterialSolvent System/Preparation DetailPhytochemical Content/Marker CompoundsStudiesGynura procumbensMAC/SOX/PARTLeaves; crude plant extractEtOH–H2O mixtures, EtOH 70–96%, MeOH 70%, H2O; partitioning with Hex, BuOH, and EtOAcChlorogenic acid, rutin, astragalin, kaempferol derivatives, quercetin, myricetin, caffeic acid, coumaric acid, lutein, luteolin[43–51]Gynura procumbensUS/HOMLeavesUltrasonication or homogenization using EtOH–H2O gradients or 65% EtOHChlorogenic acid, gallic acid, hydroxycinnamic acids, hydroxybenzoic acids, flavonoid derivatives[52,53]Gynura procumbensINF/FOOD-FORMLeaves; powdered plant materialHot-water incubation or direct incorporation into food matrixTotal polyphenols expressed as gallic acid equivalents[54–56]Gynura procumbensEND-FERM/LLEEndophytic fungi from leavesFermentation followed by EtOAc and MeOH extractionIsoelemicin, terpinen-4-ol, eucalyptol, oleic acid, phenolics, flavonoids, terpenoids[56]Mimosa pudicaMAC/PERC/PARTAerial parts, leaves, whole plant, rootsEtOH, 50–100% EtOH, 80% EtOH, MeOH, EtOH–H2O 1:1; fractionation with Hex, DCM, CHCl3, EtOAc, aqueous fractionsGallic acid, quercetin, protocatechuic acid, syringic acid, isoorientin, orientin, chlorogenic acid, shikimic acid, naringenin[57–62]Mimosa pudicaUAEWhole plantUAE with 70% EtOHStigmasta-7,16-dien-3-ol, 3-dibenzofuranamine, bufadienolide, gallic acid[63]Mimosa pudicaDEC/AQLeaves; whole plantDecoction or boiling with H2OGallic acid, vanillic acid, p-coumaric acid, quercetin[64,65]Tithonia diversifoliaMAC/UAELeavesMeOH, 70% EtOH, 80% acetone, 48–96% EtOH; ZnO nanoemulsion from ethanolic extractDihydro-p-coumaric acid, tagitinin C, gallic acid, chlorogenic acid, caffeic acid, p-coumaric acid, apigenin[66–72]Tithonia diversifoliaPART/LLE/INFLeavesH2O infusion; MeOH–H2O, acetone, Hex, CHCl3, EtOAc, BuOH, and other solvent fractionsTagitinin A, tagitinin C, 5-O-(E)-caffeoylquinic acid, luteolin, sesquiterpene lactones[73–75]Leucaena leucocephalaMAC/SOX/USSeeds, leaves, pods, fruits, fruit peelEtOH 70–80%, MeOH, absolute EtOH; Soxhlet MeOH; ultrasonication with 70% EtOHPhenolics, flavonoids, quercetin, apigenin, myricetin derivatives, glycosylated flavonoids, quercetin-3-glucoside, EGCG, naringin, phenolic acids[76–83]Leucaena leucocephalaIOXSeedsIon-exchange extraction using H2O, NH4OH, HCl, NaOH, and EtOH systemsL-mimosine[84,85]Smallanthus sonchifoliusMAC/PERC/STIR/PARTLeaves70% EtOH, EtOH–H2O 7:3, MeOH, Hex, EtOAc, BuOH, CHCl3, 99.5% EtOH and H2OCaffeic acid, chlorogenic acid, ferulic acid, gallic acid, quercetin, p-coumaric acid, dicaffeoylquinic acids, enhydrin[86–91]Smallanthus sonchifoliusINF/DECLeaves, leaves and stemsH2O infusion, tea-bag infusion, decoction; EtOH–H2O mixtures for infusionEnhydrin, enhydrofolin, chlorogenic acid, caffeic acid, coumaric acid, sesquiterpene lactones, methylated quercetin derivatives[92–95]Syzygium cuminiMAC/INF/AQSeeds, fruits, leaves, peel70% aqueous MeOH, EtOH–H2O 1:1, 70% EtOH, H2O infusion, distilled-water crushing/filtrationGallic acid, chlorogenic acid, caffeic acid, quercetin, isoquercitrin, rutin, kaempferol, lupeol, eugenol, ursolic acid, flavonoids, triterpenoids[96–100]Abbreviations: AQ, aqueous extraction; BuOH, n-butanol; CHCl3, chloroform; DCM, dichloromethane; DEC, decoction; END-FERM, endophyte fermentation-derived preparation; EtOAc, ethyl acetate; EtOH, ethanol; FOOD-FORM, food-matrix formulation; FORM, commercial or formulation-based preparation; H2O, water; Hex, hexane; HOM, homogenization-assisted extraction; INF, infusion. Plant Materials, Extraction Methods, Solvent Systems, and Phytochemical Identification Reported in the Included Studies Abbreviations: AQ, aqueous extraction; BuOH, n-butanol; CHCl3, chloroform; DCM, dichloromethane; DEC, decoction; END-FERM, endophyte fermentation-derived preparation; EtOAc, ethyl acetate; EtOH, ethanol; FOOD-FORM, food-matrix formulation; FORM, commercial or formulation-based preparation; H2O, water; Hex, hexane; HOM, homogenization-assisted extraction; INF, infusion. Mechanistic Domain Mapping Mechanistic findings were mapped to predefined cardiometabolic domains to compare the biological breadth of each plant across glucose absorption, insulin signaling, lipid metabolism, vascular and endothelial regulation, inflammatory signaling, oxidative stress, and mechanisms related to renal or cardiometabolic complications. The most frequently represented domains were insulin signaling and glucose homeostasis (n = 35 studies), oxidative stress and cytoprotection (n = 31), vascular or endothelial function (n = 24), renal or cardiometabolic complication-related mechanisms (n = 22), lipid metabolism and adipometabolic regulation (n = 21), inflammation and immune-metabolic signaling (n = 15), and glucose absorption or carbohydrate digestion (n = 13). The specific molecular targets, signaling pathways, biochemical markers, and mechanistic endpoints identified for each plant are summarized in Table 4. Table 4Mechanistic Domain Mapping of Included Studies by Plant SpeciesSpeciesGlucose Absorption /Carbohydrate DigestionInsulin Signaling/ Glucose HomeostasisLipid Metabolism/Adipometabolic RegulationVascular/Endothelial FunctionInflammation/Immune-Metabolic SignalingOxidative Stress/CytoprotectionRenal/Cardiometabolic ComplicationsGynura procumbens↓ α-glucosidase; ↓ α-amylase; ↓ postprandial glucose44,49↓ FBG; ↑ glucose tolerance; ↔ glycolytic/gluconeogenic enzymes; ↓ diabetes-induced weight loss43,49,55 (↓ TC, LDL, TG; ↑/↔ HDL49,55↓ ACE; ↑ vasorelaxation; ↓ Ca2⁺ channel activity; ↑ prostacyclin-mediated relaxation; ↓ ICAM-1, VCAM-1, MCP-1; ↑ ANG, EGF, FGF, TGF-β, VEGF45,46,48,50↓ NO, TNF-α, PGE2, COX-2; ↓ MAPK; ↓ PI3K/Akt; ↓ NF-κB activation47,50,52↑ DPPH/FRAP activity; ↑ phenolic/flavonoid-linked radical scavenging; ↑ endophyte-derived antioxidant metabolites47,53,56↔ creatinine; ↔ hepatic/renal metabolic enzymes; ↓ endothelial adhesion; ↑ diabetic wound repair and neovascularization48–50Mimosa pudica↓ α-glucosidase; ↓ α-amylase; ↓ enzyme activity by protocatechuic acid/syringic acid; ↑ enzyme inhibition in nanoparticle formulation57–59,65↑ 3T3-L1 glucose uptake; ↓ PTP1B; Pred. ↑ PPARγ interaction; ↑ GLUT1/GLUT4-related glucose transport in formulation study57,59,64,101↓ LDL, VLDL; ↑ HDL; ↓ adipometabolic risk via PTP1B inhibition59,64Limited direct evidence; Pred. PDE5 interaction; ↑ reproductive vascular/hormonal endpoints63Ø direct TNF-α/IL-6/NF-κB/COX-2 evidence in cardiometabolic models↑ DPPH/ABTS scavenging; ↑ TPC/TFC; ↓ oxidative-stress-related reproductive dysfunction57,60,61,63↑ sperm parameters; ↑ testosterone; ↔ diabetic reproductive dysfunction63Tithonia diversifoliaPred. ↓ α-glucosidase; ↓ DPP-4 activity in herb screening102Pred. ↓ DPP-4, SGLT-2, LMW-PTP; Pred. ↑ PPARγ/SUR1 interaction; ↑ fasting insulin; ↓ HOMA-IR; ↑ renal insulin receptor; ↑ mtDNA copy number67–69,102↓ TC; ↓ leptin; ↑ adiponectin; ↓ CD36; ↓ oxLDL uptake; ↓ foam-cell formation69,75Pred. ↓ ACE; ↓ monocyte–endothelial adhesion; ↓ VCAM-1, ICAM-1, E-selectin; ↓ Akt phosphorylation; ↓ NF-κB75,102↓ TNF-α, IL-35; Pred. ↓ iNOS/COX-2; ↓ leukocytes, lymphocytes, monocytes; ↓ macrophage activation67,70,75,103↑ SOD; ↑ GPx; ↓ oxidative injury; ↑ mtDNA-linked mitochondrial biogenesis signal67,68,71Pred. ↓ ALR, RAGE, ACE, DPP-4, SGLT-2; ↓ creatinine, urea, γ-GT; ↑ renal insulin receptor; ↓ renal necrosis/hemorrhage/inflammatory infiltration67,69,70,102Leucaena leucocephala↓ α-glucosidase; ↓ α-amylase; Pred. α-amylase interaction by hexadecanoic acid and oleic acid derivatives79,80,104↓ FBG; ↑ insulin; ↑ pancreatic islets; ↑ SIRT1/AMPK/PGC1-α; ↑ GLUT4 translocation76,82,104Limited direct lipid-target evidence; ↔ metabolic biochemical endpoints; flavonoid-linked adipometabolic plausibility76,82Limited direct endothelial evidence; indirect ↑ vascular relevance via antioxidant and insulin-sensitizing pathways82,104↑/↔ IL-2, IL-5, IL-6, IL-10, IL-13, IL-17, IFN-γ, TNF-α, MCP-1, MIP-1α, GM-CSF; not cardiometabolic-specific83↑ DPPH/ABTS/FRAP activity; ↑ phenolic/flavonoid-linked radical scavenging; ↑ endophyte-derived antioxidant activity76,80,82,104↔/↓ albumin, ALP, BUN, creatinine, total protein; ↓ thyroid/reproductive safety profile due to mimosine-related toxicity76,84,85Smallanthus sonchifolius↓ α-glucosidase via enhydrin; ↓ α-amylase; ↓ postprandial glucose89,90,95↓ glycemia; ↑ glucose tolerance; ↑ insulin; ↑ HOMA-β; ↑ β-cell regeneration signal; Pred. ↓ SGLT-2/DPP-4 via kestose/nystose/dicaffeoylquinic acids86–88,105,106↓ TG; ↓ fatty acids; ↔ adipometabolic status; FOS/phenolic-acid-linked metabolic modulation86,88,92Limited direct evidence; indirect ↑ vascular relevance via ↓ oxidative stress and tissue-protective effects87,91↓ IL-6, TNF-α, TGF-β1; ↓ SMAD2/3/4; ↑ SMAD787,91↑ catalase; ↑ GPx; ↓ MDA; ↑ DPPH/ABTS/FRAP activity; ↑ phenolic-acid cytoprotection86,87,90,92↓ TGF-β/SMAD fibrotic signaling; mixed renal findings: ↑ creatinine/AST/albumin in toxicity studies; renal histological alterations reported91,93,94Syzygium cuminiPred. ↓ α-glucosidase via D-(+)-catechin and flavonoids107↓ FBG; ↓ HbA1c in formulation-level clinical evidence; ↓ STZ-induced hyperglycemia96,97,99,108↓ TC, TG, LDL, VLDL; ↑ HDL; ↓ macrophage lipid accumulation; ↓ foam-cell formation96–98↓ oxLDL-induced foam-cell formation; ↓ ROS/RNS; ↓ intracellular lipid accumulation96,98↓ WBC elevation; ↓ macrophage oxidative/inflammatory activation96,98↑ SOD; ↓ MDA; ↓ ROS/RNS; ↑ polyphenol/catechin-linked antioxidant activity96–100↔ albumin, ALP, total protein in diabetic models; ↑ NOAEL margin in formulation-related toxicity assessment97,99Notes: ↑ = increase/stimulation/upregulation; ↓ = decrease/inhibition/downregulation/suppression; ↔ = normalization/restoration/modulation; Pred. = predicted in silico; Ø = no direct evidence identified. Mechanistic Domain Mapping of Included Studies by Plant Species Notes: ↑ = increase/stimulation/upregulation; ↓ = decrease/inhibition/downregulation/suppression; ↔ = normalization/restoration/modulation; Pred. = predicted in silico; Ø = no direct evidence identified. Evidence density across the seven mechanistic domains is additionally summarized as a heat map in Figure 3 (number of unique cited studies per species–domain combination). Two cross-species patterns emerge. First, mechanistic breadth was uneven: Gynura procumbens showed evidence across nearly all seven domains (glucose, lipid, vascular, inflammatory, and wound-healing pathways), the broadest of the six species, whereas Tithonia diversifolia and Smallanthus sonchifolius also showed comparably broad mechanistic evidence, but for both species this breadth was accompanied by prominent hepatic, renal, or mutagenicity signals that constrained translational interpretation (detailed in Table 4 and discussed below). Leucaena leucocephala showed a narrower but consistent antidiabetic signal (enzyme inhibition and SIRT1/AMPK/PGC1-α/GLUT4 signaling) that was likewise offset by mimosine-related toxicity. Mimosa pudica and Syzygium cumini remained the least mechanistically characterized, with evidence confined largely to in vitro/in silico or polyherbal formulation-based studies. Second, mechanistic breadth and safety were inversely related across species: the two species with the most favorable safety signals (G. procumbens and, more provisionally, M. pudica) showed narrower or still-emerging mechanistic evidence, whereas the three species with the broadest multitarget activity (T. diversifolia, L. leucocephala, and S. sonchifolius) also carried the most consistent toxicity signals, an inverse relationship discussed further below. Heat map summary of mechanistic domain evidence density by species (number of unique cited studies per domain). Safety and Toxicity Evidence Safety evidence across the six medicinal plants was uneven and preparation-dependent (Table 4). Gynura procumbens showed the most favorable short-term safety profile, with no major cytotoxic, acute, or topical toxicity signals under the tested conditions, although chronic, reproductive, and genotoxicity data remain limited. Mimosa pudica also showed generally acceptable preliminary safety in cell-based and computational assessments, but the evidence was mostly limited to in vitro or in silico models, and nanoparticle-based preparations showed concentration-dependent cytotoxicity. Syzygium cumini appeared relatively well tolerated in short-term and formulation-level studies; however, species-specific safety interpretation was restricted by the use of polyherbal or combination preparations. In contrast, Tithonia diversifolia, Leucaena leucocephala, and Smallanthus sonchifolius showed more prominent toxicological concerns, spanning extract- and constituent-dependent hepatic, renal, mutagenic, and reproductive endpoints; species- and preparation-specific details are summarized in Table 4, and the extent to which these signals might be mitigated is considered in the Discussion. Discussion Diabetes mellitus (DM) is a chronic metabolic disease characterized by hyperglycemia resulting from impaired insulin secretion, reduced insulin sensitivity, or both, which also disrupts lipid, carbohydrate, and protein metabolism.109 Antihyperglycemic agents act through complementary mechanisms, including reduced intestinal glucose absorption, stimulated insulin secretion, incretin pathway modulation, suppressed hepatic glucose production, improved peripheral insulin sensitivity, and central glucose regulation.110 This diversity of targets provides a useful framework for evaluating natural-product candidates alongside synthetic drugs. Interest in plant-derived antihyperglycemic agents has grown owing to their structural diversity, multitarget potential, and generally favorable safety profiles: terpenes, tannins, flavonoids, saponins, and alkaloids have been reported to lower glucose through α-glucosidase/α-amylase inhibition, hypolipidemic activity, and enhanced glucose uptake and insulin secretion.111 This systematic review provides a comparative analysis of the multitarget pharmacological mechanisms and safety profiles of six ethnobotanically prioritized Indonesian medicinal plants—Gynura procumbens, Mimosa pudica, Tithonia diversifolia, Leucaena leucocephala, Smallanthus sonchifolius, and Syzygium cumini—with relevance to cardiovascular and metabolic diseases, drawing on in silico, in vitro, and in vivo evidence. Overall, the six species show diverse, overlapping pharmacological activity attributable to their rich phytochemistry, generally coupled with an acceptable short-term safety profile; several methodological and translational limitations nonetheless warrant consideration. Gynura procumbens Gynura procumbens, commonly known as longevity spinach or sambung nyawa in Indonesia, is a member of the Asteraceae family with a well-documented array of pharmacological activities. These includes anticancer activities by inducing apoptosis and suppressing metastasis in cancers,112 antihypertensive action via ion channels inhibition,113 and attenuation of postprandial hyperglycemia.114 Its bioactivity is largely attributed to a a diverse phytochemicals constituent dominated by phenolic compounds, including chlorogenic acid, hydroxycinnamic acids (including caffeic acid, caffeoylquinic acid isomers, dicaffeoylquinic acids, and coumaroylquinic acids), hydroxybenzoic acids (protocatechuic acid, gallic acid glucoside), and flavonoid derivatives (quercetin rutinoside, kaempferol rutinoside, luteolin derivatives).55 Among its most therapeutically relevant properties is its anti-inflammatory activity. Gynura procumbens downregulates the MAPK and P13K/Akt signaling pathway, thereby reducing the secretion of proinflammatory factors, including nitric oxide (NO), TNF-α, and PGE-2, as well as the expression of COX2 proteins.49,54 This mechanism is of particular relevance in the context of diabetes, as inflammatory cytokines are known to contribute to beta-cell damage in Type 1 diabetes. Furthermore, both brown adipose tissue and visceral white adipose tissue have been identified as major sources of inflammatory markers, while simultaneously serving as targets of inflammatory processes in individuals with Type 2 diabetes.115 The antihyperglycemic potential of G. procumbens has been substantiated by both in vitro and in vivo evidence. In vitro, G. procumbens extract demonstrated significant, dose-dependent inhibition of α-glucosidase and α-amylase, with IC50 values of 0.092 mg/mL and 0.084 mg/mL, respectively. These inhibitory effects are mechanistically attributed to the flavonoid constituents of its extract, which are postulated to interfere with the hydrophobic and hydrophilic binding interactions of digestive enzymes, thereby decelerating carbohydrate hydrolysis and subsequent intestinal glucose absorption.45 Pharmacokinetic analysis in in vivo rat models revealed that the extract reached peak plasma concentration at 3 hours and 45 minutes post-administration, a profile comparable to that of metformin.51 In a 14-day sub-chronic study, administration of 25% G. procumbens produced the greatest reductions in fasting blood glucose—49.38% and 65.43% on days 7 and 14, respectively—values closely mirroring those achieved with metformin (46.26% and 65.42%). G. procumbens extract also significantly attenuated streptozotocin (STZ)-induced body weight loss, limiting the decline to approximately 5% compared to 16% in untreated diabetic controls.46 G. procumbens’s benefits extend beyond glucose lowering. The extract has also been shown to exhibit a vasodilatory effect and to inhibit ACE activity.48,113 In diabetic rats, G. procumbens extract improved gonadal hormone regulation and upregulated proteins essential for sperm maturation and fertilization, including cysteine-rich secretory protein 1, carboxylesterase 5A, zona pellucida binding protein, and phosphatidylethanolamine-binding protein 1. Histological analysis further revealed restoration of seminiferous tubule architecture and spermatogenesis, accompanied by increased implantation rates in female rats mated with treated males.56 Treatment with the extract also helped normalize disturbed lipid profiles (total cholesterol, LDL, triglycerides, and HDL), liver enzymes (SGOT and SGPT), creatinine levels, and glycolytic and gluconeogenic enzyme activities in both the liver and kidney of the rats.51 Additionally, the extract has been shown to attenuate early atherosclerotic processes through reduced monocyte adhesion to endothelial cells and suppression of NF-κB signaling pathway activation.52 Topical application of the extract has also demonstrated notable wound-healing efficacy. A 0.5% G. procumbens extract formulation reduced wound healing time by 30% in healthy mice and 40% in diabetic mice, outperforming the commercial reference agent solcoseryl jelly, particularly in the diabetic group. These effects are attributed to enhanced neovascularization, as evidenced by upregulation of angiogenic growth factors—including ANG, EGF, FGF, TGF-β, and VEGF—in wound tissue, as well as promoted proliferation and migration of keratinocytes, fibroblasts, and endothelial cells, and a notable increase in mast cell recruitment.50 Beyond the phytoconstituents of the leaves, the endophytic fungi isolated from Gynura procumbens leaves, particularly Macrophomina phaseolina SN6, are believed to contribute to the well-documented bioactive properties of their host plant, as these fungi produced many of the same classes of compounds—including phenolics, flavonoids, and terpenoids such as eucalyptol and β-pinene—known to underlie the antioxidant and antimicrobial activities traditionally attributed to G. procumbens. This suggests that even in conventional plant extract preparations where the fungi are not deliberately isolated, these endophytes remain present within the plant tissue and continue to contribute their bioactive metabolites to the overall extract, meaning that the therapeutic activities long attributed solely to G. procumbens may in fact reflect a combined contribution from both the plant and its resident endophytic fungi.58 Collectively, the safety profile of G. procumbens further supports its candidacy as a natural antihyperglycemic agent. G. procumbens exhibited no cytotoxic effects on 3T3-L1 cells at concentrations up to 2 mg/mL,45 and acute toxicity studies in rats demonstrated a wide safety margin—a dose 50-fold higher than the medium therapeutic dose produced no lethality, in stark contrast to metformin, which resulted in 100% rat mortality at the equivalent dose.51 Mimosa pudica Mimosa pudica, or also known as Laajvanti, touch-me-not, shame plant, or putri malu in Indonesia, is a perennial herb native to Tropical America.116 Its principal chemical constituents include mimosine, tannins, and a range of flavonoids—notably apigetrin, orientin, isoorientin, quercetin, gallic acid, and ellagic acid.117,118 Phytochemical characterization of the ethyl acetate fraction revealed a total phenolic content of 164.21 ± 1.81 mg GAE/g and a total flavonoid content of 64.89 ± 4.70 mg QE/g, alongside notable antioxidant activity with an IC50 of 21.39 ± 3.76 μg/mL.62 Mimosa pudica demonstrates considerable potential as an insulin-mimetic and anti-inflammatory agent. In silico evaluation identified apigetrin and orientin as potent ligands with high binding affinity at the PPAR-γ receptor (−8.6 and −8.5 kcal/mol, respectively), surpassing the reference drug pioglitazone.103 Further supporting its antidiabetic potential, protocatechuic acid and syringic acid isolated from M. pudica demonstrated meaningful inhibitory activity against both α-glucosidase (IC50: 416.17 and 490.78 μM, respectively) and protein tyrosine phosphatase 1B (PTP1B) (IC50: 248.83 and 450.31 μM, respectively), suggesting a dual-target mechanism. Specifically, α-glucosidase inhibition reduces postprandial glucose absorption, while PTP1B inhibition enhances insulin sensitivity and may confer additional benefits in the management of obesity.61 In vitro assays confirmed that the 1% extract successfully reduced glucose level by 7.4 mg/dL in liver cells due to its GLUT-inhibition activity.53 The extract was two to three times more potent than acarbose in inhibiting α-glucosidase, while glucose uptake in 3T3-L1 cells co-treated with insulin was five-fold higher than that of the untreated control.59 The IC50 of the extract was 56.65 ± 4.33 μg/mL for α-glucosidase inhibitory activity.60 In vivo, M. pudica not only reduced blood glucose levels but also improved the lipid profile in diabetic animal models, lowering LDL and VLDL cholesterol while raising HDL. When the leaf extract was combined with strontium nanoparticles (SrNPs), dose-dependent inhibition of both α-amylase and α-glucosidase reached approximately 85%, a level comparable to the reference drug acarbose.67 Beyond its metabolic action, M. pudica extract has been shown to improve sexual behavior, testosterone levels, and overall reproductive function in diabetic male rats, attributed to its capacity to attenuate oxidative stress and facilitate the restoration of hormonal balance.65 Overall in silico toxicity prediction revealed that the constituents of M. pudica did not exhibit hepatotoxicity, AMES toxicity or skin sensitization.63 Cytotoxicity assessment via the brine shrimp lethality assay revealed a progressive, concentration-dependent reduction in nauplii survival with increasing strontium nanoparticles concentrations over 48 hours, indicating cytotoxic potential that may warrant further investigation for drug development applications.67 Tithonia diversifolia Tithonia diversifolia (Asteraceae), commonly known as Mexican sunflower or insulin leaf, is native to North and Central America but has since spread to Asia, Australia, and Africa.119 The plant is phytochemically characterized by its rich sesquiterpene lactone content, particularly tagitinin C, orizabin, tithonine, and diversifolin, alongside phenolic acids such as chlorogenic acid and caffeic acid.73 In silico studies predict that several of these active constituents possess promising antidiabetic mechanisms: tithonine has been identified as a potential SGLT-2 inhibitor, while diversifolin acts as a potent α-glucosidase inhibitor. More broadly, phytoconstituents of T. diversifolia have demonstrated superior binding affinity toward multiple proteins implicated in the pathogenesis of diabetic nephropathy, including α-glucosidase, angiotensin-converting enzyme (ACE), aldose reductase (ALR), dipeptidyl peptidase-4 (DPP-4), low molecular weight protein tyrosine phosphatase (LMW-PTP), peroxisome proliferator-activated receptor-γ (PPAR-γ), receptor for advanced glycation end products (RAGE), sodium-glucose cotransporter 2 (SGLT-2), and sulfonylurea receptor 1 (SUR1).104 Beyond its action against diabetic protein, several constituents from the combination of T. diversifolia, Moringa oleifera and Curcuma longa extract, namely xanthurenic acid, piperanine, ferulic acid, and 57-dihydroxy-4-methylcoumarin has shown activity toward iNOS (binding affinity −8.2, −8.8, −7.2, and −8.6 kcal/mol, respectively) and COX-2 (−7.9, −8.1, −7.2, and −8.0 kcal/mol, respectively), demonstrating its anti-inflammatory potential in relation to insulin resistance and dysfunction of pancreatic β-cell.105 In vivo findings further substantiate the systemic benefits of T. diversifolia. In diabetic rats treated with the extract at 100 mg/kg body weight for seven days, significant reductions were observed in blood glucose levels, pro-inflammatory cytokines (IL-35 and TNF-α), and hematological parameters including leukocyte, lymphocyte, and monocyte counts, relative to untreated diabetic controls. The extract also reduced total cholesterol and leptin concentrations while increasing adiponectin levels and renal insulin receptor expression. Histological examination revealed attenuation of kidney damage—including necrosis, hemorrhage, and inflammatory cell infiltration—suggesting a protective role against diabetic nephropathy.71,72 Anti-diabetic activity is also shown by improved fasting insulin, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) score, and increased mtDNA copy number of in stretozotocin-niacinamide induced diabetic rats model, which suggests an improvement in mitochondrial biogenesis.70 Numerous studies have indicated that insulin resistance is closely linked to decreased mitochondrial content and impaired oxidative capacity in insulin-sensitive tissues, which led researchers to propose that compromised mitochondrial function may contribute substantially to the pathogenesis of insulin resistance and subsequently type 2 diabetes.120 The potential of the extract to be developed into a pharmaceutical dosage form has been demonstrated in a study employing a ZnO nanoemulsion formulation, which significantly reduced blood glucose, creatinine, urea, γ-GT, and TNF-α levels (p ≤ 0.05), while enhancing the activities of superoxide dismutase, glutathione peroxidase, and insulin levels.69 T. diversifolia also demonstrates anti-atherosclerotic potential. Orizabin, a compound isolated from the extract significantly reduced monocyte adhesion to inflamed endothelial cells through suppression of adhesion molecules—including VCAM-1, ICAM-1, and E-selectin—while also inhibiting macrophage differentiation, CD36 expression, and oxidized LDL (oxLDL) uptake in THP-1 cells, accompanied by suppression of NF-κB activity and inhibition of Akt phosphorylation.77 These effects collectively attenuate the inflammatory responses and foam cell formation central to atherosclerotic progression. Regarding safety, acute and sub-acute toxicity studies of dihydrocoumaric acid derived from T. diversifolia in BALB/c mice reported no deaths, behavioral abnormalities, or significant organ damage at oral doses up to 1600 mg/kg (acute) and 500 mg/kg (sub-acute), although mild elevations in hepatic enzymes (ALT and AST) indicated slight hepatotoxicity at higher doses.68 The aqueous extract, as commonly employed in traditional medicine, was found to be relatively safe at doses below 100 mg/kg; however, mild hematological alterations and elevated AST levels suggestive of hepatic stress were observed at higher doses. In contrast, the chlorogenic acid-rich extract induced significant liver toxicity, manifesting as steatosis and biochemical alterations in ALT, AST, triglycerides, albumin, and creatinine, while the sesquiterpene lactone-rich extract produced severe renal damage characterized by glomerular and tubular degeneration, accompanied by systemic signs of toxicity including dyspnea and asthenia. Catechin, tithonine, and diversifolin from the plant have also shown a low toxicity during in silico prediction. However, they were indicated to be mutagenic in the AMES test and needed further in vitro and in vivo validation to confirm the mutagenicity of these three compounds.104 For traditional uses, safe consumption is recommended at up to 250 mL of 2% tea per day.71 These findings collectively indicate that both sesquiterpene lactones and chlorogenic acid derivatives contribute to the toxic profile of T. diversifolia during prolonged administration—the former predominantly affecting the kidneys and the latter the liver—and therefore warrant careful consideration in its therapeutic use.75,76 Several strategies may help mitigate the hepatic and renal risk of T. diversifolia. Because toxicity tracked with specific chemical fractions rather than the crude leaf itself, preparation method appears to be a controllable variable: the aqueous extract remained comparatively safe below 100 mg/kg, whereas isolating or removing the sesquiterpene lactone- and chlorogenic acid-rich fractions could plausibly separate antidiabetic activity from renal and hepatic liability, respectively. Establishing a defined sub-toxic dose ceiling below the thresholds associated with hepatic enzyme elevation, pairing extract use with periodic liver- and kidney-function monitoring, and prioritizing purified or nanoformulated preparations (eg, the ZnO nanoemulsion already shown to lower creatinine, urea, and TNF-α) over crude extracts are practical near-term mitigation options. Confirmatory in vitro/in vivo mutagenicity testing of catechin, tithonine, and diversifolin is also needed before the AMES-positive in silico signal can be dismissed or acted upon. Leucaena leucocephala Leucaena leucocephala, a member of the Fabaceae family, is a species originating from Central America and Mexico.121 Metabolomic analysis has identified 65 distinct compounds across its active extracts, encompassing flavonoids, phenolic acids, and coumarins. Notable bioactive constituents include quercetin, apigenin, myricetin, kaempferol, and myricetin derivatives, all of which are recognized for their antioxidant and antidiabetic properties.81,122 A defining phytochemical characteristic of L. leucocephala is its high mimosine content. Mimosine is a non-protein amino acid with metal-chelating properties, to which its documented toxicity in animals is primarily attributed.123 Despite the presence of measurable total phenolic content (37.38 mg GAE/g), DPPH assay revealed only moderate to weak antioxidant activity, with an EC50 of 839.56 µg/mL compared to 1.48 µg/mL for vitamin C.78 Preclinical evidence nonetheless supports the antidiabetic potential of L. leucocephala. In vivo studies demonstrated that seed extracts reduced blood glucose levels and increased the number of pancreatic islets of Langerhans, while in vitro assays confirmed high antibacterial activity in pod extracts. The extract exhibited potent in vitro α-glucosidase inhibitory activity, with an IC50 value of 3.43 ± 0.05 µg/mL,81 and moderate α-amylase inhibitory activity (IC50 = 288.01 µg/mL).82 This activity can be attributed to the presence of hexadecanoic acid and (Z)-octadec-9-enoic acid, which bind in the active site of α-amylase during in silico molecular docking (binding affinity (−1.313 kcal/mol and −1.266 kcal/mol, respectively).82 In STZ-induced diabetic rats, the seed extract significantly reduced fasting blood glucose (from 281.25 to 182.87 mg/dL relative to untreated diabetic controls) and elevated serum insulin levels, suggesting partial preservation or stimulation of beta-cell function. Biochemical analysis, however, revealed that while the extract reduced elevated alkaline phosphatase (ALP) and total protein levels, it also significantly lowered albumin and failed to normalize elevated blood urea nitrogen (BUN) and creatinine, raising concerns regarding potential adverse effects on renal function.78 The antidiabetic and antioxidant potential of L. leucocephala has also been further explored through its endophytic microbiota. A bacterial endophyte isolated from its leaves, identified via 16S rRNA gene sequencing as Cronobacter sakazakii, yielded an ethyl acetate crude extract. Enzyme inhibition assays yielded IC50 values of 23.3 µg/mL and 23.4 µg/mL for α-amylase and α-glucosidase inhibition, respectively, approximating the potency of the reference drug acarbose. Acute toxicity testing confirmed a favorable safety margin, with an LD50 exceeding 2,000 mg/kg. In vivo, L. leucocephala at 200 mg/kg produced significant blood glucose reductions at 8 and 12 hours post-administration in both glucose-loaded normal rats and STZ-induced diabetic rats, though the effect in the diabetic model was somewhat less pronounced than that of glibenclamide.106 L. leucocephala has been shown to exhibit antibacterial effects by targeting the DNA gyrase and topoisomerase I, with highest activity against Escherichia coli and lowest activity against Bacillus subtilis.79 L. leucocephala has also demonstrated antihelmintic activity, reducing egg production and worm burden in mice infected with Caeonorhabditis elegans by approximately 50%, while simultaneously stimulating immune responses through enhanced production of Th1-, Th2-, and Th17-related cytokines and chemokines, including IL-2, IL-5, IL-6, IL-10, IL-13, IL-17, IFN-γ, TNF-α, MCP-1, MIP-1α, and GM-CSF.85 This effect may be explained by the presence of 132-hydroxy-(132-S)-pheophytin in L. leucocephala seeds.80 This anthelmintic activity was also observed when the extract was combined with extracts of Gliricidia sepium and Pithecellobium dulce, demonstrating in vitro inhibitory effects against Haemonchus contortus larval exsheathment and egg hatching, with IC50 values of 43.35 and 4.31 mg/mL, respectively.83 However, the therapeutic promise of L. leucocephala is substantially tempered by the toxicological profile of mimosine. Despite its benefit, mimosine is known to have low aqueous and organic solubility—which complicates conventional dosing—enabling the exploration of alternative formulation strategies. Administration of gelatin tablets containing 140 mg/kg L-mimosine daily did not significantly affect hematological, biochemical, reproductive, or fetal developmental parameters in pregnant rats.86 At higher doses, however, rats exhibited markedly reduced testosterone levels, decreased mounting frequency, and prolonged mounting latency, collectively indicating impaired male reproductive performance. Biochemical analysis further revealed reductions in total protein and albumin, while T3 and T4 hormone levels showed a declining trend, though without reaching statistical significance. These findings support the hypothesis that L-mimosine, or its metabolites, can induce thyroid dysfunction and reproductive toxicity even in monogastric animals, likely through interference with hormone synthesis, DNA replication, and cellular function.87 Accordingly, caution is warranted regarding the use of L. leucocephala as forage, food, or medicinal material, and future research should prioritize strategies to exploit its bioactive constituents while mitigating the risks associated with mimosine exposure. Concretely, several mimosine-mitigation approaches already established in forage science could be adapted for pharmaceutical use of L. leucocephala: mimosine content can be substantially lowered by water-soaking, boiling, or fermentation of plant material prior to extraction, and by microbial degradation using mimosine-metabolizing bacteria; chelation-based co-formulation (eg, with ferrous sulfate) can reduce mimosine bioavailability; and fractionating the extract to enrich for the flavonoid/phenolic constituents responsible for antidiabetic activity while depleting the mimosine-rich fraction could decouple efficacy from endocrine and reproductive risk. Because reproductive toxicity was dose-dependent (140 mg/kg L-mimosine was tolerated in pregnant rats, whereas higher doses impaired male reproductive function), establishing a validated no-observed-adverse-effect dose and avoiding use during pregnancy or the reproductive period are additional near-term safeguards, alongside periodic monitoring of thyroid and reproductive hormone levels in any future clinical evaluation. Smallanthus sonchifolius Smallanthus sonchifolius, commonly known as yacon, is notable for its richness in fructooligosaccharides (FOS) and polyphenols, including phenolic acids such as caffeic acid, chlorogenic acid, ferulic acid, and gallic acid, as well as sesquiterpene lactones, among which enhydrin is particularly prominent.88 Preclinical evidence supports the antidiabetic potential of S. sonchifolius through multiple mechanisms. In fed diabetic rats, the extract reduced blood glucose and improved glucose clearance in both oral and intravenous glucose tolerance tests, indicative of enhanced insulin sensitivity rather than reduced intestinal glucose absorption. Notably, the extract had no effect on blood glucose in normal or fasting rats, suggesting an absence of hypoglycemic risk. A further study reported that S. sonchifolius extract reduced blood glucose by 63.39% and insulin levels by 49.30% in diabetic rats.90 Enhydrin, a compound found in S. sonchifolius leaves, has been known to inhibit α-glucosidase in baker’s yeast (IC50 = 134.17 ± 42.00 μg/mL) and reducing blood gluose levels by 38.32 ± 1.64 mg/dl in diabetic rat model and increasing plasma insulin level.91,97 The extract has also been known to inhibit α-amylase during in vitro study (IC50 37.86 µg/mL).92,124 The proposed mechanism underlying these effects involves the partial regeneration of pancreatic beta cells, supported by improvements in the HOMA-β (Homeostasis Model Assessment of Beta Cell Function) score and elevated insulin levels in streptozotocin-induced diabetic rats.89 In silico analysis identified 1-kestose as a candidate SGLT-2 inhibitor. Molecular docking further revealed four compounds—3,4-dicaffeoylquinic acid, nystose, 1,3-O-dicaffeoylquinic acid, and 3,5-dicaffeoylquinic acid—with promising inhibitory activity against DPP-4, exhibiting binding affinities (rerank scores of −99.168 to −118.13 kcal/mol) surpassing that of the reference drug alogliptin (−105.306 kcal/mol) and interacting with key active site residues including Glu205, Glu206, Ser209, Tyr547, and Ser630.108 Despite these promising properties, safety considerations surrounding S. sonchifolius merit careful attention. Cytotoxicity testing on CHO-K1 and HepG2 cell lines demonstrated a concentration-dependent reduction in cell viability. Cytome assays revealed significant genotoxic effects in both lines, including increased frequencies of micronuclei, nucleoplasmic bridges, and nuclear buds, indicative of both clastogenic and aneugenic potential. HepG2 cells exhibited these effects only at substantially higher concentrations, suggesting that hepatic biotransformation partially mitigates, but does not fully counteract, the genotoxic activity of the extract.95 The polyphenol-enriched extract (PE) produced only minor biochemical changes without serious organ lesions, suggesting relative safety at the doses tested. The leaf raw extract (LRE), however, proved highly toxic, causing mortality at 1,000 mg/kg within days and pronounced signs of toxicity at 100 mg/kg. The aqueous extract (AE), despite reflecting the preparation method commonly used in traditional tea consumption, induced significant elevations in creatinine, blood glucose, albumin, AST, and total proteins across all doses tested; histological examination of renal tissue confirmed glomerular damage, cellular infiltration, and tubular alterations consistent with chronic renal injury.96 These findings suggest that preparation choice, rather than the species itself, is the primary driver of S. sonchifolius toxicity and is therefore the most tractable point for mitigation. The polyphenol-enriched extract produced only minor, reversible biochemical changes, whereas the leaf raw extract and aqueous (tea-type) extract were considerably more toxic; favoring polyphenol-enriched or purified preparations over raw leaf or aqueous infusions, and avoiding the higher end of tested dose ranges, would likely reduce renal and cytotoxic risk while retaining antidiabetic activity. Given the concentration-dependent genotoxicity observed in CHO-K1 and HepG2 cells, in vitro genotoxicity screening (eg, micronucleus assay) of any candidate extract batch, together with renal-function monitoring in future in vivo or clinical work, is a reasonable minimum safeguard before further development. Syzygium cumini Syzygium cumini, also known as black plum, java plum, jamun, jambolan or jamblang, has long been recognized as an effective antidiabetic agent, with traditional use spanning several ethnomedical systems.125 It is a member of Myrtaceae family, the tree has been found in South Asia, mainly in Pakistan, India, as well as the Asia Pacific, including Indonesia, Philippines, Hawaii, and Australia.126 In Ayurvedic practice, Syzygium cumini is frequently used in traditional medicine in combination with other plant extracts to enhance its therapeutic efficacy. It is employed as a component of a polyherbal formulation known as Pancreas Tonic, alongside Momordica charantia, Gymnema sylvestre, and Trigonella foenum-graecum. A randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes mellitus demonstrated that participants with higher baseline HbA1c levels (10–12%) who received Pancreas Tonic experienced a significant reduction in HbA1c from 10.1% to 8.8%, while placebo-treated patients showed no improvement. However, no significant effects were observed on fasting plasma glucose, lipid profile, blood pressure, body composition, insulin sensitivity, or meal challenge responses.127 Another study evaluated the extract in combination with extracts of Ficus benghalensis and Ocimum sanctum, demonstrating a significant antihyperglycemic effect in rats, with fasting blood glucose (FBG) reductions of 32.9–43.7% was observed after 2 hours and further 37.1–55.3% reduction after 4 weeks of treatment.99 The principal bioactive constituents of S. cumini include alkaloids, flavonoids, saponins and triterpernoids, with catechin, myricetin, and morin identified as key compounds.101,128 In silico analysis indicates that D-(+)-catechin exhibits the highest binding affinity toward the α-glucosidase receptor.128 In vivo, male Sprague-Dawley rats with streptozotocin-induced type 2 diabetes that were administered with S. cumini extract at doses of 50 mg/kg and 100 mg/kg body weight for 14 days showed statistically significant reductions in fasting blood glucose (p < 0.0001), with the higher dose yielding the most pronounced effect, comparable in direction to the metformin-treated positive control.101 Beyond glycemic regulation, S. cumini demonstrates notable atheroprotective potential of relevance to diabetic patients with concurrent cardiovascular complications. Macrophages pre-treated with S. cumini extract prior to oxidized LDL (oxLDL) exposure exhibited reduced levels of reactive oxygen and nitrogen species (ROS/RNS) and diminished intracellular lipid accumulation compared to untreated controls.100 Given that lipid accumulation in macrophages drives foam cell formation and subsequent atherosclerotic plaque development, these findings suggest a meaningful role for S. cumini in mitigating the vascular sequelae of diabetes. Comparative preclinical studies have further contextualized the efficacy of S. cumini relative to other botanicals. When evaluated alongside Ficus carica, both extracts dose-dependently reduced fasting blood glucose, body weight, total cholesterol, triglycerides, LDL, and VLDL, while increasing HDL levels in an obesity-linked type 2 diabetes model. Both plants also improved oxidative stress markers, reflected in increased superoxide dismutase (SOD) activity and decreased malondialdehyde (MDA) levels; however, S. cumini consistently demonstrated superior efficacy across most parameters.98 The rich phytochemicals in S. cumini are believed to contribute to its activity, which is beneficial not only for pharmacological applications but also for food preservation The antioxidant effect is not only beneficial as a pharmacological agent. A study showed that by pectin-based edible coatings enriched with Syzygium cumini peel and leaf extracts which could preserve the quality of minimally processed fruits over 9 days of refrigerated storage (5 ± 2°C).102 The no-observed-adverse-effect level (NOAEL) of the extract was determined to be greater than 5000 mg/kg body weight, indicating a relatively high safety margin under the tested conditions.99 Limitations and Translational Considerations Several limitations should be considered when interpreting the findings of this review. First, the evidence base is overwhelmingly preclinical: the large majority of included studies were in silico, in vitro, or animal-based, whereas controlled clinical evidence in humans was minimal or absent for most species. This imbalance means that the mechanistic breadth described for each plant, particularly the multitarget profile of Gynura procumbens, should not be read as evidence of clinical efficacy, and the discussion above should be understood as a synthesis of biological plausibility rather than demonstrated human benefit. Second, the evidence is not uniform in kind: findings derived from isolated, structurally defined compounds, from crude or partially characterized extracts, from polyherbal formulations combining the target species with other botanicals, and from purely computational (in silico) predictions carry different degrees of interpretive certainty, and effects observed for a polyherbal formulation or an isolated marker compound cannot be attributed with confidence to the whole-plant extracts most commonly used in traditional practice. Third, methodological heterogeneity across the included studies, in plant part used, extraction solvent and method, dose range, animal or cell model, and outcome metric, together with the general absence of standardized, chemically characterized extracts, limits direct comparability between studies and contributed to conflicting or only partially concordant findings for several species; this heterogeneity is also the principal reason a meta-analysis was not undertaken. Fourth, this review is subject to potential publication bias, as studies reporting positive pharmacological findings are more likely to be published than negative or null results, and to geographic bias, since the included evidence is concentrated in Indonesian and neighboring Southeast Asian research groups and may not generalize to other populations, growing conditions, or chemotypes of the same species. Grey literature and non-indexed regional journals were not systematically searched, which may have further concentrated the evidence base. Restricting the systematic search to PubMed and Scopus, although these two databases together offer broad and complementary biomedical coverage and were supplemented by reference-list screening, may still have missed records indexed exclusively in other databases (eg, Web of Science, CAB Abstracts, or regional repositories); this restriction is therefore acknowledged as a limitation, and future updates of this review should consider a multi-database search to further maximize sensitivity. Fifth, standardization challenges, including the absence of validated reference markers, certified reference extracts, and harmonized dosing units across studies, together with essentially no pharmacokinetic, bioavailability, or herb–drug interaction data for any of the six species, represent major regulatory and clinical translation barriers; because most cardiometabolic patients receive concurrent antidiabetic, antihypertensive, or lipid-lowering medication, the potential for pharmacokinetic or pharmacodynamic herb–drug interactions is a clinically important but essentially unstudied risk for all six species. Finally, no validated, study-type-agnostic risk-of-bias instrument was applied across the heterogeneous evidence base, and the quality appraisal performed here was therefore descriptive rather than a formal, scored risk-of-bias assessment. Future research should prioritize standardized extract characterization and certified reference markers, formal risk-of-bias and GRADE-type certainty assessment, dedicated pharmacokinetic and herb–drug interaction studies, chronic and reproductive toxicity testing for species with preliminary toxicity signals, and well-designed, adequately powered randomized clinical trials, conducted in accordance with applicable regulatory frameworks, before any of the six species can be considered for clinical application. Conclusion In summary, this systematic review synthesizes the mechanistic, pharmacological, and safety evidence for six ethnobotanically prioritized medicinal plants investigated for cardiometabolic diseases, and highlights their translational potential as candidates for future evidence-based phytopharmaceutical development rather than as therapies ready for clinical use. Among six ethnobotanically medicinal plants, Gynura procumbens was characterized with the largest mechanistic range from glucose regulation, vascular protection, to wound healing, and had the best short-term safety profile. On the other hand, despite the robust antidiabetic activity of Tithonia diversifolia, Leucaena leucocephala, and Smallanthus sonchifolius, which showed multi-target activities in vitro, the possibility for clinical application is greatly hampered by severe toxic effects involving liver, kidney, and mimosine-induced reproductive toxicity. Finally, the majority of findings on Mimosa pudica and Syzygium cumini are based on preliminary, in vitro, in silico, or polyherbal formulation-based investigations. Because the evidence base for all six species remains predominantly preclinical, with standardized extract characterization, chronic and reproductive toxicity data, and controlled clinical evidence still lacking, none of these plants can currently be recommended for clinical application. Future investigations should therefore prioritize standardized extract characterization and certified reference markers, rigorous chronic and reproductive toxicity studies, pharmacokinetic and herb–drug interaction evaluation, and well-designed, adequately powered randomized clinical trials to establish clinical efficacy and safety before these ethnobotanically prioritized species can be considered for cardiometabolic drug development. Funding Statement This research is funded by the Indonesian Endowment Fund for Education (LPDP) on behalf of the Indonesian Ministry of Higher Education, Science and Technology and managed under the EQUITY Program (Contract No. 4302/B3/DT.03.08/2025 and 573/PKS/R/UI/2025) through scheme Riset Kolaborasi Indonesia awarded to FAS (contract number PKS-185/UN2.R3/HKP.05.00/2025). Disclosure The author(s) report no conflicts of interest in this work. References